文献速递血脂与心血管预防

依洛尤单抗在6000余例患者中的汇总安全性分析

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.
PubMed 文献 · Circulation · 2017-03-01

该汇总安全性分析纳入12项2/3期母试验的6026例患者(中位暴露2.8个月)及2项开放标签扩展试验中继续治疗的4465例患者(中位随访11.1个月),评估依洛尤单抗的不良事件。结果显示,母试验和OLE试验第一年的总体不良事件率、严重不良事件率在依洛尤单抗组与对照组间相似,转氨酶、胆红素和肌酸激酶升高少见且组间相似,未检出中和性抗依洛尤单抗抗体,支持依洛尤单抗具有良好的获益-风险特征。

要点

  • 母试验中依洛尤单抗组与对照组总体不良事件率分别为51.1%与49.6%,严重不良事件率相似。
  • OLE试验第一年依洛尤单抗组与对照组总体不良事件率分别为70.0%与66.0%,严重不良事件率相似。
  • 未检出中和性抗依洛尤单抗抗体,支持依洛尤单抗的获益-风险特征良好。

核心结论

  • 汇总6026例2/3期试验患者及4465例OLE试验继续治疗1年的患者,依洛尤单抗的安全性结果支持其良好的获益-风险特征。

研究设计与样本

  • 汇总分析纳入12项2/3期随机、安慰剂或对照药对照的母试验(6026例患者,中位暴露2.8个月)及2项开放标签扩展试验中继续治疗的4465例患者(中位随访11.1个月)。
  • 不良事件分别在母试验和OLE试验中分析,评估总体不良事件率、严重不良事件、实验室指标及关注的不良事件。

主要发现

  • 母试验中依洛尤单抗组与对照组总体不良事件率分别为51.1%与49.6%,严重不良事件率相似。
  • OLE试验第一年依洛尤单抗组与对照组总体不良事件率分别为70.0%与66.0%,严重不良事件率相似。
  • 血清转氨酶、胆红素和肌酸激酶升高少见且组间相似,肌肉相关不良事件组间相似。
  • 双盲母试验中神经认知不良事件少见且均衡:依洛尤单抗组5例事件(0.1%) vs 对照组6例事件(0.3%)。
  • OLE试验中依洛尤单抗组27例患者(0.9%) vs 对照组5例患者(0.3%)报告神经认知不良事件。

关键数值与推荐

  • 母试验中依洛尤单抗组与对照组总体不良事件率分别为51.1%与49.6%。
  • OLE试验第一年依洛尤单抗组与对照组总体不良事件率分别为70.0%与66.0%。
  • 双盲母试验中神经认知不良事件:依洛尤单抗组5例事件(0.1%) vs 对照组6例事件(0.3%)。
  • OLE试验中神经认知不良事件:依洛尤单抗组27例患者(0.9%) vs 对照组5例患者(0.3%)。
  • 未检出中和性抗依洛尤单抗抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein convertase subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol across diverse patient populations. The objective of this study was to assess the safety and tolerability of evolocumab in a pooled safety analysis from phase 2 or 3 randomized and placebo or comparator-controlled trials (integrated parent trials) and the first year of open-label extension (OLE) trials that included a standard-of-care control group. METHODS: This analysis included adverse event (AE) data from 6026 patients in 12 phase 2 and 3 parent trials, with a median exposure of 2.8 months, and, of those patients, from 4465 patients who continued with a median follow-up of 11.1 months in 2 OLE trials. AEs were analyzed separately for the parent and OLE trials. Overall AE rates, serious AEs, laboratory assessments, and AEs of interest were evaluated. RESULTS: Overall AE rates were similar between evolocumab and control in the parent trials (51.1% versus 49.6%) and in year 1 of OLE trials (70.0% versus 66.0%), as were those for serious AEs. Elevations of serum transaminases, bilirubin, and creatine kinase were infrequent and similar between groups. Muscle-related AEs were similar between evolocumab and control. Neurocognitive AEs were infrequent and balanced during the double-blind parent studies (5 events [0.1%], evolocumab groups versus 6 events [0.3%], control groups). In the OLE trials, 27 patients (0.9%) in the evolocumab groups and 5 patients (0.3%) in the control groups reported neurocognitive AEs. No neutralizing antievolocumab antibodies were detected. CONCLUSIONS: Overall, this integrated safety analysis of 6026 patients pooled across phase 2/3 trials and 4465 patients who continued in OLE trials for 1 year supports a favorable benefit-risk profile for evolocumab.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Toth PP, Descamps O, Genest J, et al. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017. PMID: 28249876. doi:10.1161/CIRCULATIONAHA.116.025233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。